Physician profile
Lanice Thomas
NPI 1215550371
$2,038.70
in general payments reported to CMS, 2019-2025
24 companies · $1,220 in 2025
The $1,220 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $818 · 2025: $1,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,038.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $219.79 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $214.89 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $207.37 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $166.22 | 2024-2025 | Airsupra, Farxiga |
| Intuitive Surgical, INC. | $109.68 | 2025 | |
| Phathom Pharmaceuticals, INC. | $107.81 | 2024-2025 | Voquezna |
| Pfizer INC. | $104.05 | 2024-2025 | |
| Lilly USA, LLC | $93.70 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Corcept Therapeutics | $85.84 | 2025 | Korlym |
| Kyowa Kirin, INC. | $76.41 | 2024-2025 | Crysvita |
| Insulet Corporation | $75.28 | 2024-2025 | Omnipod |
| Shield Therapeutics INC | $74.85 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.89 | 2024-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $66.81 | 2024-2025 | Rexulti |
| Madrigal Pharmaceuticals | $65.70 | 2025 | Rezdiffra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $53.48 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.12 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $49.74 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Biogen, INC. | $45.79 | 2025 | Zurzuvae |
| Daiichi Sankyo INC. | $29.00 | 2025 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $18.36 | 2025 | Eohilia |
| Alk-Abello, INC | $16.35 | 2025 | Grastek, Ragwitek, Odactra |
| Janssen Pharmaceuticals, INC | $15.83 | 2025 | Spravato |
| Amgen INC. | $14.74 | 2024 | Prolia, Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lanice Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.